Efficacy and safety of erdosteine in the treatment of chronic rhinosinusitis with nasal polyposis - a pilot study
| Autor: | Kellnerova R, Petr Schalek, Ivo Stárek, Jiří Hoza, Richard Salzman |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class Chronic rhinosinusitis Anti-Inflammatory Agents Erdosteine Pilot Projects Thiophenes Young Adult Nasal Polyps Internal medicine medicine Humans Prospective Studies Sinusitis Adverse effect Tumor necrosis factor α Pregnadienediols Aged Expectorants Rhinitis Nasal endoscopy business.industry General Medicine Middle Aged Treatment Outcome Otorhinolaryngology Thioglycolates Chronic Disease Corticosteroid Drug Therapy Combination Female business Mometasone Furoate medicine.drug |
| Zdroj: | Rhinology journal. 51:323-327 |
| ISSN: | 0300-0729 |
| Popis: | Background: Erdosteine was originally developed as a mucolytic agent. It is a multimechanism substance with anti-bacterial, anti-oxidant, and most importantly anti-inflammatory effects. Given similar mechanisms of action (suppression of cytokines, including tumor necrosis factor α), it could become a reasonable alternative to currently used treatments with macrolides or steroids. Objective: To assess efficacy and safety of erdosteine in the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). Methodology: A prospective non-interventional post-authorisation study comparing patients treated with erdosteine only or the combination of erdosteine and nasal corticosteroid spray for CRSwNP. The end-points were pre- and post-treatment changes in endoscopic score and subjective evaluation of CRSwNP related symptoms using a 22-item Sinonasal Outcome Test questionnaire. Patients underwent nasal endoscopy and filled the questionnaire before and after the treatment. Results: No patient experienced any adverse effect during the study. A comparison of pre- and post-treatment endoscopic findings and questionnaire values revealed significant reduction in both patient groups, with a significantly better response in the erdosteine only group. Conclusion: Based on this pilot study, erdosteine seems effective in the treatment of CRSwNP and might become a reasonable alternative to currently used medication. The therapeutical role of erdosteine needs to be further assessed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|